A 58-year-old male smoker presents with a 3-month history of cough and hemoptysis. CT chest shows a 4 cm peripheral mass in the right lower lobe. Bronchoscopy and biopsy confirm adenocarcinoma of the lung. Staging workup reveals stage IIIA disease (T3N2M0) with no distant metastases. The patient is deemed suitable for concurrent chemoradiotherapy. Which of the following is the drug of choice for chemotherapy in this regimen?

Explanation

## First-Line Chemotherapy for Concurrent Chemoradiotherapy in NSCLC **Key Point:** Cisplatin with etoposide is the preferred chemotherapy regimen for concurrent chemoradiotherapy in locally advanced NSCLC (stage III disease). ### Rationale for Cisplatin + Etoposide 1. **Radiosensitization**: Etoposide is a topoisomerase II inhibitor with proven radiosensitizing properties, making it ideal for concurrent delivery with thoracic radiation. 2. **Historical evidence**: The RTOG 94-10 trial and subsequent meta-analyses established cisplatin + etoposide as the standard for concurrent chemoradiotherapy in unresectable stage III NSCLC. 3. **Tolerability in concurrent setting**: This combination has a well-characterized toxicity profile when given concurrently with radiation, allowing predictable dose modifications. ### Comparison of Chemotherapy Regimens in NSCLC | Regimen | Setting | Mechanism | Radiosensitizer | Notes | |---------|---------|-----------|-----------------|-------| | Cisplatin + Etoposide | Concurrent CRT (stage III) | Platinum + Topo II inhibitor | Yes (etoposide) | Gold standard for concurrent CRT | | Cisplatin + Pemetrexed | Maintenance/advanced NSCLC | Platinum + antifolate | No | Better for non-squamous, not for CRT | | Carboplatin + Paclitaxel | Advanced/metastatic NSCLC | Platinum + microtubule inhibitor | Weak | More commonly used in sequential CRT | | Gemcitabine + Vinorelbine | Advanced NSCLC | Antimetabolite + vinca alkaloid | No | Older regimen, less commonly used now | **High-Yield:** Cisplatin + etoposide is the **only** regimen specifically validated for **concurrent** chemoradiotherapy in stage III NSCLC. Other combinations are used for sequential therapy or advanced disease. **Clinical Pearl:** In patients with renal impairment or significant hearing loss, carboplatin-based regimens may be substituted, but cisplatin + etoposide remains the preferred standard when feasible. **Warning:** Do not confuse cisplatin + pemetrexed (used in advanced non-squamous NSCLC and maintenance therapy) with cisplatin + etoposide (concurrent CRT). Pemetrexed is not a radiosensitizer and is not indicated for concurrent chemoradiotherapy. ### Treatment Algorithm for Stage III NSCLC ```mermaid flowchart TD A[Stage III NSCLC]:::outcome --> B{Resectable?}:::decision B -->|Yes| C[Surgery + adjuvant chemotherapy]:::action B -->|No| D{Performance status adequate?}:::decision D -->|Yes| E[Concurrent chemoradiotherapy]:::action D -->|No| F[Sequential CRT or radiation alone]:::action E --> G[Cisplatin + Etoposide]:::action G --> H[Thoracic radiation 60-66 Gy]:::action H --> I[Consolidation therapy consideration]:::action ``` [cite:Harrison 21e Ch 107]